Browsing by Author "Ince, I"

Now showing 1 - 7 of 7
  • No Thumbnail Available
    Item
    Vitamin D protects against hippocampal apoptosis related with seizures induced by kainic acid and pentylenetetrazol in rats
    Sahin, S; Gürgen, SG; Yazar, U; Ince, I; Kamasak, T; Arslan, EA; Durgut, BD; Dilber, B; Cansu, A
    Objectives: The hippocampus is susceptible to damage in patients with epilepsy and in animals with seizures caused by excitotoxic agents. The effect of vitamin D on hippocampal apoptosis related with seizures has not been reported. However, epileptic patients have an increased risk of hypovitaminosis D which is most likely due to the effects of antiepileptic drugs. Therefore, in this study, it was aimed to evaluate the effects of vitamin D on hippocampal apoptosis related with seizures by using pentylenetetrazol (PTZ) and kainic acid (KA) in rats. Methods: Male Sprague Dawley rats, aged 5.5 weeks, were randomly divided into six groups: control, vitamin D, PTZ, KA, PTZ + vitamin D and KA + vitamin D groups. The groups that received vitamin D were given 500 IU/kg of vitamin D daily for two weeks in addition to a standard diet. At the end of this period, PTZ and KA were applied to trigger seizures in the rats in the seizure groups. 24 h after the administration of PTZ and KA, the rats were decapitated. In the hippocampal region, apoptosis was assessed by TUNEL and brain-derived neurotrophic factor (BDNF), Bax, caspase-3 and c-fos activation were evaluated by immunohistochemical method. Results: BDNF level increased while c-fos, Bax and caspase-3 levels decreased (p < 0.0001, in all) in the hippocampal neurons of the groups that were pre-treated with vitamin D before the administration of PTZ and KA, in comparison with the PTZ and KA groups. Vitamin D significantly decreased the number of apoptotic cells in these rats in comparison with the PTZ and KA groups (p < 0.0001). Conclusion: This study indicates that vitamin D has neuroprotective effects on hippocampal apoptosis induced by PTZ and KA in rats. With this study it is suggested that keeping vitamin D levels within normal limits may be beneficial for patients with epilepsy, especially children.
  • No Thumbnail Available
    Item
    Thymoquinone Glucuronide Conjugated Magnetic Nanoparticle for Bimodal Imaging and Treatment of Cancer as a Novel Theranostic Platform
    Ince, I; Müftüler, ZB; Medine, EI; Güldü, ÖK; Takan, G; Ergönül, A; Parlak, Y; Yildirim, Y; Çakar, B; Bilgin, ES; Aras, Ö; Göker, E; Ünak, P
    Background: Theranostic oncology combines therapy and diagnosis and is a new field of medicine that specifically targets the disease by using targeted molecules to destroy the cancerous cells without damaging the surrounding healthy tissues. Objective: We aimed to develop a tool that exploits enzymatic TQ release from glucuronide (G) for the imaging and treatment of lung cancer. We added magnetic nanoparticles (MNP) to enable magnetic hyperthermia and MRI, as well as 131I to enable SPECT imaging and radionuclide therapy. Methods: A glucuronide derivative of thymoquinone (TQG) was enzymatically synthesized and conjugated with the synthesized MNP and then radioiodinated with 131I. New Zealand white rabbits were used in SPECT and MRI studies, while tumor modeling studies were performed on 6-7-week-old nude mice utilized with bioluminescence imaging. Results: Fourier-transform infrared spectroscopy (FTIR) and nuclear magnetic resonance (NMR) spectra confirmed the expected structures of TQG. The dimensions of nanoparticles were below 10 nm and they had rather polyhedral shapes. Nanoparticles were radioiodinated with 131I with over 95% yield. In imaging studies, in xenograft models, tumor volume was significantly reduced in TQGMNP-treated mice but not in non-treated mice. Among mice treated intravenously with TQGMNP, xenograft tumor models disappeared after 10 and 15 days, respectively. Conclusion: Our findings suggest that TQGMNP in solid, semi-solid and liquid formulations can be developed using different radiolabeling nuclides for applications in multimodality imaging (SPECT and MRI). By altering the characteristics of radionuclides, TQGMNP may ultimately be used not only for diagnosis but also for the treatment of various cancers as an in vitro diagnostic kit for the diagnosis of beta glucuronidase-rich cancers.
  • No Thumbnail Available
    Item
    A new dressing material in diabetic wounds: Wound healing activity of oleuropein-rich olive leaf extract in diabetic rats
    Samancioglu, S; Esen, A; Ercan, G; Mansoub, NH; Vatansever, S; Ince, I
    Introduction: The objective of this study was to evaluate a dressing material on ischemic wound model in diabetic rats. Study was conducted during the months of June 2012-March 2013 at Ege University in Izmir, Turkey. Materials and Methods: Sprague Dawley rats weighing 200-250 g obtained from an experimental animal production center (Saki Yenili-Ankara,Turkey) were used in this study. Animals were randomly assigned to diabetic (n= 20) and nondiabetic (n= 20) groups. After diabetes induction and wound creation, animals within each group were assigned to two wound dressing groups by a second randomization. The study was carried out on these four groups. After diabetes induction and wound creation, animals within each group (n= 10) were assigned to olive leaf extract (OLE) wound dressing and normal saline (sodium chloride, 0.9% NaCI) wound dressing groups by a second randomization. 0.9% NaCl and OLE dressing was applied to wounds once a day by the researcher. The areas of wounds were measured by Walker Formula. OLE wound dressing healed wounds faster and earlier than classic wound dressing (p< 0.05). Results: In the diabetic group; wounds closure time was found to be 24.80 +/- 1.48 in OLE wound dressing and 28.00 +/- 2.31 days in classical wound dressing. Conclusion: As a result in terms of success ratios, OLE wound dressing for wound healing in diabetic and non-diabetic wounds has been determined to be more effective in comparison with classic wound dressing method.
  • No Thumbnail Available
    Item
    Retrospective and multicenter analysis of efficacy and safety of ruxolitinib in 176 Turkish patients with myelofibrosis: updated data
    Soyer, N; Ali, R; Turgut, M; Haznedaroglu, I; Yilmaz, F; Aydogdu, I; Pir, A; Karakus, V; Ozgur, G; Kis, C; Ceran, F; Ilhan, G; Ozkan, M; Arslaner, M; Ince, I
  • No Thumbnail Available
    Item
    EFFICACY AND SAFETY OF RUXOLITINIB IN TURKISH PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS: A MULTICENTER AND RETROSPECTIVE ANALYSIS
    Soyer, N; Turgut, M; Haznedaroglu, I; Yilmaz, F; Aydogdu, I; Pir, A; Karakus, V; Ozgur, G; Kis, C; Ceran, F; Ilhan, G; Ozkan, M; Arslaner, M; Ince, I; Yavasoglu, I
  • No Thumbnail Available
    Item
    Efficacy and safety of ruxolitinib in patients with myelofibrosis: a retrospective and multicenter experience in Turkey
    Soyer, N; Ali, R; Turgut, M; Haznedaroglu, IC; Yilmaz, F; Aydogdu, I; Pir, A; Karakus, V; Özgür, G; Kis, C; Ceran, F; Ilhan, G; Özkan, M; Aslaner, M; Ince, I; Yavasoglu, I; Gediz, F; Sönmez, M; Güvenç, B; Özet, G; Kaya, E; Vural, F; Sahin, F; Töbü, M; Durusoy, R; Saydam, G
    Background/aim: The aim of this study is to assess the efficacy and safety of ruxolitinib in patients with myelofibrosis. Materials and methods: From 15 centers, 176 patients (53.4% male, 46.6% female) were retrospectively evaluated. Results: The median age at ruxolitinib initiation was 62 (28-87) and 100 (56.8%) of all were diagnosed as PMF. Constitutional symptoms were observed in 84.7%. The median initiation dose of ruxolitinib was 30 mg (10-40). Dose change was made in 69 (39.2%) patients. Forty seven (35.6%) and 20 (15.2%) of 132 patients had hematological and nonhematological adverse events, respectively. The mean spleen sizes before and after ruxolitinib treatment were 219.67 +/- 46.79 mm versus 199.49 +/- 40.95 mm, respectively (p < 0.001). There was no correlation between baseline features and subsequent spleen response. Overall survival at 1-year was 89.5% and the median follow up was 10 (1-55) months. We could not show any relationship between survival and reduction in spleen size (p = 0.73). Conclusion: We found ruxolitinib to be safe, well tolerated, and effective in real-life clinical practice in Turkey. Ruxolitinib dose titration can provide better responses in terms of not only clinical benefit but also for long term of ruxolitinib treatment.
  • No Thumbnail Available
    Item
    Prospective Real-World Outcomes of Acute Myeloid Leukemia
    Karakus, V; Iltar, U; Yenihayat, EM; Polat, MG; Celik, S; Malkan, UY; Seval, GC; Dogan, A; Akdeniz, A; Pinar, IE; Ozdalci, D; Ince, I; Erdem, R; Mehtap, O; Kirkizlar, HO; Kacmaz, M; Deveci, B; Aykas, F; Akat, GK; Kaya, SY; Ozturk, HBA; Sevindik, O; Can, F; Cekdemir, D; Aslan, C; Bulbul, H; Guven, ZT; Maral, S; Durusoy, SS; Demirkan, F; Goker, H; Ozkalemkas, F; Keklik, M; Toprak, SK; Yucel, EE; Atas, U; Alacacioglu, I